PAPER OF THE MONTH - MAY 2020
Cellular and humoral responses to an adenoviral vector vaccine against RSV: a first-in-human RCT.
Cicconi P, Jones C, Sarkar E, Silva-Reyes L, Klenerman P, de Lara C, Hutchings C, Moris P, Janssens M, Lisette LA, Picciolato M, Leach A, Gonzalez-Lopez A, Dieussaert I and D.Snap M.
This paper presents the results of a novel chimpanzee-derived replication-deficient adenoviral vector
vaccine against RSV (ChAd155-RSV), based on 3 RSV viral proteins including F (fusion), N
(nucleocapsid), and M2-1 (antitermination). Although the intended use is in the infant population,
this phase 1 first-in-human study aimed to investigate safety, reactogenicity, and immunogenicity of
ChAd155-RSV in healthy adults aged 18–45 years. Adenoviral vector vaccines have shown to be able
to elicit long-term cellular and humoral immune responses and are efficient in delivering foreign
antigens into host cells. Although potent, the immune response elicited by this type of vaccine is
dependent on the recipient’s immune status. While ChAd155-RSV antibodies could decrease the
overall efficacy of the vaccine and preexisting anti-RSV NAb could mask the humoral response, a
vaccine response was seen in about 60% of the high-dosage group and 20% in the low-dosage group.
The key value of this study is confirmation of the ability of viral vector vaccines to intrinsically
promote a combined cellular and humoral immune response to one of the most important
pathogens in infancy. With low levels of preexisting antibodies against both RSV and adenovirus in
the pediatric population, the potency of these vaccines in eliciting a vaccine response may be higher
compared to the adult population.
Cicconi P, Jones C, Sarkar E, Silva-Reyes L, Klenerman P, de Lara C, Hutchings C, Moris P, Janssens M, Lisette LA, Picciolato M, Leach A, Gonzalez-Lopez A, Dieussaert I and D.Snap M.
This paper presents the results of a novel chimpanzee-derived replication-deficient adenoviral vector
vaccine against RSV (ChAd155-RSV), based on 3 RSV viral proteins including F (fusion), N
(nucleocapsid), and M2-1 (antitermination). Although the intended use is in the infant population,
this phase 1 first-in-human study aimed to investigate safety, reactogenicity, and immunogenicity of
ChAd155-RSV in healthy adults aged 18–45 years. Adenoviral vector vaccines have shown to be able
to elicit long-term cellular and humoral immune responses and are efficient in delivering foreign
antigens into host cells. Although potent, the immune response elicited by this type of vaccine is
dependent on the recipient’s immune status. While ChAd155-RSV antibodies could decrease the
overall efficacy of the vaccine and preexisting anti-RSV NAb could mask the humoral response, a
vaccine response was seen in about 60% of the high-dosage group and 20% in the low-dosage group.
The key value of this study is confirmation of the ability of viral vector vaccines to intrinsically
promote a combined cellular and humoral immune response to one of the most important
pathogens in infancy. With low levels of preexisting antibodies against both RSV and adenovirus in
the pediatric population, the potency of these vaccines in eliciting a vaccine response may be higher
compared to the adult population.
On 12- 14 November 2019 ReSViNET Foundation heldt its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. We look back on a successful, exciting and inspiring meeting. Our special thanks to our sponsors to make this event possible and our chairs and scientific advisory board. Last but not least we thank all the speakers and participants for their contributions. |
AWARENESS OF RSV AS A GLOBAL HEALTH PROBLEM IS LACKING
|
To raise and spread awareness, we have launched a ‘RSV Mortality Awareness’ campaign at the start of the RSVVW2019 conference on November 12, by sharing a personal video entitled “Why we should all know about RSV” about Simone van Wyck, a mother who lost her son due to RSV. The RSV awareness video was produced in collaboration with the Bill & Melinda Gates Foundation.
|
|
ABOUT RESVINET FOUNDATIONRSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. |
ReSViNET Foundation is certified by NGOsource as equivalent to a U.S. public charity!
|
|
We would like to express our sincere condolences to Neeltjes' family for their loss. Jan. 2020.
Neeltje from The Netherlands, 99 years old, participant of the RESCEU Older adults study. RSV is an important cause of pneumonia in older adults. Awareness of RSV in older adults is almost absent. Every year about 3-6% of all older adults are infected with RSV. Course of disease is most severe on older adults with severe underlying disease such as heart failure or COPD. |
ReSViNET Global partners
